Arhiva autor

Iolanda Muntean

Latest posts by Iolanda Muntean (see all)

Articole semnate de acelasi autor in Revista Romana de Pediatrie:

A case of giant hydronephrosis associated with arterial hypertension

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LXI, Nr. 2, An 2012
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

A case of giant hydronephrosis associated with arterial hypertension

, , , and

ABSTRACT

Cases of giant hydronephroses are rare and usually contain no more than 1-2 liters of fluid in the collecting system. We report a case of giant hydronephrosis with secondary transitory arterial hypertension. An overweight 14-year-old boy was incidentally discovered with high blood pressure at a routine medical visit. Medical history was unremarkable. Abdominal ultrasound revealed a giant cystic tumor fi lling over then 50% of abdominal cavity. Although both clinical symptoms and physical exam were poor and arterial hypertension seemed obesityinduced, finally high blood pressure was secondary to the giant hydronephrosis. Therefore, any abdominal cystic mass even in the absence of other evident pathologies should include the differential diagnosis of a possible hydronephrosis.

Key words: giant hydronephrosis, hypertension, child

Full text | PDF

UN CAZ DE HIDRONEFROZA GIGANTA ASOCIATA CU HIPERTENSIUNE ARTERIALA

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LXI, Nr. 2, An 2012
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

UN CAZ DE HIDRONEFROZA GIGANTA ASOCIATA CU HIPERTENSIUNE ARTERIALA

, , , and

REZUMAT

Cazurile de hidronefroză gigantă sunt rare şi, de obicei, nu conţin mai mult de 1-2 litri de lichid în sistemul colector. Prezentăm un caz de hidronefroză gigantă însoţită de hipertensiune arterială (HTA) tranzitorie secundară. Cu ocazia unui examen de rutină, unui pacient de 14 ani, supraponderal, i-au fost descoperite valori crescute ale teniunii arteriale. Istoricul medical a fost nesemnificativ. Ecografia abdominală a evidenţiat o tumoră chistică gigantă ce ocupa peste 50% din cavitatea abdominală. Deşi simptomele clinice cât şi examenul fizic au fost sărace, iar iniţial HTA părea indusă de obezitate, în cele din urmă HTA s-a dovedit a fi secundară hidronefrozei gigante. Prin urmare, diagnosticul diferenţiar al unei formaţiuni abdominale chistice, chiar şi în absenţa altor patologii evidente, ar trebui să includă o posibilă hidronefroză.

Cuvinte cheie: hidronefroză gigantă, hipertensiune, copil

Full text | PDF

Prophylaxis with Palivizumab in infants with congenital heart disease

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LXII, Nr. 2, An 2013
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

Prophylaxis with Palivizumab in infants with congenital heart disease

, , , , , and

ABSTRACT

Introduction. Human respiratory syncytial virus infections in children suffering from congenital heart disease is a primary cause of cardiac decompensation, which leads to frequent and prolonged hospitalizations. We will be sharing our department’s experience with utilizing Palivizumab in newborns and infants with hemodynamically significant congenital heart diseases.

Methods. According to recommendations made by immune prophylaxis guides regarding Palivizumab, 28 children with mean age 2,6 months hospitalized in the Cardiology Clinic II- Children, of the County Emergency Clinical Hospital in Tîrgu Mureş were included in a vaccination program between October 2010 and February 2012. The administered dose was 15 mg/kg (monthly intramuscular injection). Each child treated with Palivizumab was monitored in order to establish the hospitalization rate for respiratory infections, as well as detect any adverse reactions. A control group of 28 children, with a mean age of 4,3 months, with severe CHD was selected. The rate of respiratory infections was observed. The case group was monitored for 6 months after vaccination and the rate of bronchyolitis was observed.

Results. The hospitalization rate for respiratory infection was 3,57% in the case group, and 32% in the control group. Monitoring the side effects after vaccination showed no severe adverse reactions: 19% of the children developed subfebrility and slight anxiety and 4% developed fever and diarrhea 24 hours after administration.

Conclusion. The results show a favorable response to the vaccine, with minor side effects, an absence of hemodynamic decompensation at the time of administration, as well as a reduced number of human respiratory syncytial virus infections.

Key words: congenital heart disease, Palivizumab, infant

Full text | PDF

PROFILAXIA CU PALIVIZUMAB LA SUGARII CU MALFORMATII CARDIACE CONGENITALE

SELECT ISSUE

Revista Romana de PEDIATRIE | Volumul LXII, Nr. 2, An 2013
ISSN 1454-0398  |  e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

PROFILAXIA CU PALIVIZUMAB LA SUGARII CU MALFORMATII CARDIACE CONGENITALE

, , , , , and

REZUMAT

Introducere. Infecţiile respiratorii cauzate de virusul sinciţial respirator la copiii cu malformaţii cardiace congenitale reprezintă o importantă cauză de decompensare, care determină spitalizări repetate, cu durată prelungită. Prezentăm experienţa centrului nostru privind utilizarea profilactică a Palivizumab la copiii sub 24 de luni, internaţi cu malformaţii cardiace congenitale semnificative hemodinamic. Material şi metodă. În conformitate cu recomandările ghidurilor privind profilaxia cu Palivizumab, 28 de copii cu vârsta medie de 2,6 luni, internaţi în Clinica Cardiologie II Copii a Spitalului Clinic Judeţean de Urgenţă Târgu-Mureş, au fost incluşi în programul de vaccinare, în perioada octombrie 2010 – februarie 2012. Pe perioada spitalizării s-au monitorizat parametrii hemodinamici, s-a notat orice reacţie adversă apărută, precum şi rata infecţiilor respiratorii. Părinţii au semnat un consimţământ informat privind acordul pentru vaccinare. A fost selectat un grup control care nu a beneficiat de vaccin (28 copii, vârsta medie 4,3 luni), urmărindu-se rata infecţiilor respiratorii pe perioada derulării programului. La lotul imunizat am monitorizat rata îmbolnăvirilor respiratorii 6 luni postimunizare. Rezultate. Rata îmbolnăvirilor respiratorii la lotul imunizat a fost de 3,57%, iar la lotul control 32%. Efectele secundare postvaccinare: 18% au prezentat subfebrilitate şi uşoară iritabilitate, iar 4% febră şi diaree la 24 de ore după administrare. La lotul imunizat nu au apărut decompensări hemodinamice. Concluzii. Efectele secundare postvaccinare au fost minore, nu au apărut decompensări hemodinamice, iar rata de îmbolnăvire postimunizare a fost redusă.

Cuvinte cheie: malformaţii cardiace congenitale, Palivizumab, sugar

Full text | PDF